Skip to main navigation Skip to search Skip to main content

A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)

  • Stirling, Robert (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusFinished
Effective start/end date22/06/21 → 31/12/25

Keywords

  • Non-Cystic Fibrosis Bronchiectasis
  • Respiratory medicine
  • Clinical trial

Clinical Trial Phase

  • Phase III (a & b)